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Abstract
Background: Patients with severely reduced left-ventricular ejection fraction carry a high risk of morbidity and
mortality after cardiac surgery. Levosimendan can be used prophylactically in these patients having shown positive
effects on short-term outcome. However, effects on long-term outcome and patient subgroups benefiting the most
are unknown. We aim to address these topics with real-life data from our clinical practice.
Methods: Two hundred eigthy eight patients with preoperative LVEF ≤ 35% underwent cardiac surgery with
cardiopulmonary bypass between 2009 and 2013. Thereof, 246 were included in the matched analysis. Eigthy two
patients received 12.5mg Levosimendan starting at induction of anesthesia. Outcomes of patients undergoing
coronary artery bypass grafting surgery (n = 103), isolated valve surgery/ascending aortic surgery (n = 45) and those
undergoing combination procedures (n = 98) were analyzed separately. Additionally, multivariate regression analysis
was conducted in order to identify predictors of short-term outcome parameters for different subgroups of
patients.
Results: Thirty days mortality rates of 16% in the Levosimendan group and 21% in the control group (OR 0.7; 95%–
CI 0.36–1.5; p = 0.37) were observed. Levosimendan showed a positive effect on postoperative renal function. A
higher rate of new-onset atrial fibrillation (OR 4.0; 95%–CI 2.2–7-2; p < 0.0001) was observed in the Levosimendan
group. Follow-up until three years postoperatively showed no differences in long-term survival between the groups.
Conclusion: Prophylactic administration of Levosimendan did not affect overall short- and long-term outcomes.
The value of prophylactic use of Levosimendan remains questionable and more data is needed to confirm
subgroups that might benefit most.
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Background
Levosimendan (LS) improves myocardial contractility
without increasing myocardial oxygen demand by in-
creasing calcium-sensitivity of the myocardial contractile
units through binding to troponin C [1]. Furthermore, it
induces systemic vascular and coronary artery dilation
through activation of adenosine triphosphate (ATP)-
dependent potassium channels in the vascular smooth
muscle cells [2]. The effect of LS and its metabolite OR-
1896 are reported to last up to seven days [1]. LS effects
have been thoroughly investigated in the treatment for
acutely decompensated chronic heart failure, showing
positive results when compared to either dobutamine
(RUSSLAN study) or placebo (LIDO study) [3, 4]. How-
ever, the REVIVE I and II studies showed adverse effects
on those patients treated with LS [5].
Patients with preoperatively severely reduced ventricu-
lar contractility undergoing cardiac surgery with cardio-
pulmonary bypass (CPB) carry a substantial risk of
postoperative low cardiac output syndrome with its con-
sequences (organ malperfusion, shock, multi-organ fail-
ure). The advantageous properties of LS make it a
promising therapeutic or even prophylactic option for
prevention of these complications.
A number of small-sized prospective randomized trials
have shown positive effects of prophylactic LS adminis-
tration on postoperative cardiac performance [6, 7],
renal function [8, 9], inflammation [10], demand on
other inotropic drugs [11] as well as on short-term sur-
vival [12, 13]. However, the transferability of these excel-
lent results to real-life practice has been questioned and,
despite LS being one of the best-investigated drugs in
cardiovascular medicine in the recent years, its prophy-
lactic use in cardiac surgery has not become a widely
established therapeutic concept. Furthermore, the poten-
tial durability of the LS effect resulting in improved
long-term survival has not been shown so far [14, 15]. In
order to give an update from the clinical routine and to
generate hypotheses for further studies, we investigated,
if the effect of prophylactic LS administration on short-
term outcome can be confirmed in patients with pre-
operative LVEF ≤35% undergoing cardiac surgery out-
side the controlled setting of prospective trials.
Furthermore we aimed to describe for the first time the
effect of prophylactic LS on long-term survival in these
patients. Also, dependence of the LS effect on complex-
ity of the surgical procedure was investigated.
Methods
Study design
The present study was a retrospective single-center
study. It aimed to describe the effect of prophylactic LS
administration in patients with preoperative LVEF ≤35%
undergoing cardiac surgery with the use of CPB.
Ethics
The ethical committee of the Faculty of Medicine at Jus-
tus Liebig University Giessen, Germany approved the
study. The trial was designed and conducted in accord-
ance to the Declaration of Helsinki.
Study population
Patients with preoperative LVEF ≤ 35% who underwent
cardiac surgical procedures with CPB at our institution
between 01/2009 and 12/2013 where identified from in-
stitutional patient records and data issued to the nation-
wide quality assurance program. Clinical records of
these patients were reviewed and long-term survival was
determined by obtaining the patients’ excerpts from the
German federal residents’ registry. In order to correct
for relevant differences in baseline characteristics, a 1:2-
propensity score matching of LS group and control
group was conducted (Fig. 1).
Administration of LS
Patients received 12.5 mg LS via continuous intravenous
infusion over 24 h starting at the induction of anesthesia.
We did not apply an initial bolus. The treating surgeon
and the anesthesiologist decided whether to administer
prophylactic LS on an individual basis. Besides the LVEF,
determined using the biplane Simpson method, criteria
for LS use included preoperative state of cardiac com-
pensation (clinical features evaluated during the pre-
operative visit: presence of dyspnea at rest, orthopnea,
edema), hemodynamic reaction to induction of
anesthesia (decrease of systolic blood pressure by
>30mmHg without immediate stabilization after admin-
istration of inotropes, vasopressors or volume resuscita-
tion) as well as complexity and estimated duration of the
surgical intervention.
Perioperative management
Perioperatively, medical circulatory support and
hemodynamic monitoring was managed at the discretion
of the treating intensive care physicians according to the
relevant guidelines [16].
Endpoints
Outcomes were compared between patients who re-
ceived prophylactic LS and patients who did not. In
order to clarify if the effect of prophylactic LS might be
different depending on the complexity of surgery, out-
comes were further analyzed separately for patients who
underwent isolated coronary artery bypass grafting sur-
gery (CABG group), isolated valve or aortic surgery
(valve group) or combination procedures (combi group)
respectively.
The primary endpoint of the trial was postoperative
30-days survival. Long-term survival functions were
Grieshaber et al. Journal of Cardiothoracic Surgery  (2016) 11:162 Page 2 of 11
determined and compared using Kaplan-Meier estima-
tion. Secondary endpoints included postoperative need
for medical and mechanical circulatory support, renal
function, new-onset atrial fibrillation as well as lengths
of intensive care unit (ICU) stay and hospital admission.
Statistics
In this retrospective study, a descriptive statistical ana-
lysis was performed using SPSS Version 22 (IBM,
Armonk, USA), GraphPad Prism version 6 software
(GraphPad Software, Inc., La Jolla, CA, USA) and R ver-
sion 3.1.2. Patient characteristics were compared using
Fisher’s exact test or Student’s t-test as appropriate. In
order to correct for potential confounding baseline pa-
rameters between the LS group and the control group,
propensity score matching of the groups was performed.
Covariates included in the matching were age, gender,
BMI, preoperative LVEF, pulmonary hypertension (cate-
gorized into no, moderate, severe), EuroSCORE II, pre-
operative chronic kidney injury (categorized into no,
stadium 1, stadium 2, stadium 3 and stadium 4) and
weight of the intervention (categorized in isolated
CABG, isolated aortic/valve surgery, combination pro-
cedure). Hereafter, nearest neighbor matching in a 1:2
(LS : Control) fashion was performed. The maximum
caliper between matched participants was set at 0.2.
Group comparison for postoperative outcome parame-
ters was performed by Fisher’s exact test or Student’s t-
test between LS group and control group. Long-term
survival functions were determined using Kaplan-Meier
estimation and compared using the log rank test.
The effect of LS administration on the clinical out-
come parameters ‘30-days survival’, ‘postoperative acute
kidney injury (as defined by the AKIN-Criteria [17])’ and
‘postoperative new-onset atrial fibrillation within 24h
post-surgery’ was additionally estimated by multivariate
regression using generalized linear models. Survival data
was fitted using Cox-proportional hazard models. Some
metric predictors were log-transformed to linearize their
relationship with the response (see Additional file 1 for
detailed model formulations and coefficient tables).
Results
Study population
Of all patients who underwent cardiac surgical proce-
dures with CPB at our institution between 01/2009 and
12/2013, 288 patients presented with preoperative LVEF
< 35%. Thereof, 84 patients received LS prophylactically,
204 did not receive LS. Before propensity score match-
ing, differences in preoperative renal function, previously
known pulmonary hypertension and prevalence of re-
cent acute myocardial infarction between the groups
were observed. In the matched study population (n =
246; LS: n = 82; Control n = 164), these differences were
eliminated and patients’ baseline characteristics were
balanced between the groups (Table 1; Additional file 2).
Fig. 1 Patient inclusion flow chart. From 3.951 patients operated on in the inclusion period, 288 presented with preoperative LVEF ≤35%. Of
these, 84 patients received prophylactic LS and 204 did not. After propensity score matching, 246 patients remained in the analysis with 82
patients in the LS group and 164 patients in the control group. Abbreviations: CABG: Coronary artery bypass grafting surgery, LS: Levosimendan,
LVEF: Left-ventricular ejection fraction
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The procedural profiles showed a tendency towards more
complex procedures in the LS group compared to the
control group with 39% vs. 43% isolated CABG proce-
dures and 46% vs. 37% combination procedures (p = 0.16).
Isolated valve surgery and surgery on the thoracic aorta
were evenly distributed between the groups (Table 1).
Altogether, patients in both groups represented a high-
risk patient population with EuroSCORE II values of
19.0% in the LS group and 17.1% in the control group
(p = 0.41) (details of the EuroSCORE II – relevant pa-
rameters: Additional file 2). Of note, CABG patients in
the LS group had higher EuroSCORE II compared to
the control group (15.8% vs.12.6%; p = 0.56) and valve
group patients who received LS had lower EuroSCORE
II values compared to the control group (13.7% vs. 20.9%;
p = 0.37). Blood pressure at induction of anesthesia as well
as duration of CPB and cardioplegic arrest were similar in
both groups (Table 1).
Postoperative medical and mechanical circulatory support
The proportions of patients requiring postoperative med-
ical support with epinephrine, norepinephrine, milrinone
and dobutamine as well as the duration of application of
these agents in these patients is shown in Table 2. Overall,
83% of LS patients compared with 68% of the control
group patients required epinephrine (p < 0.001). Duration
Table 1 Baseline characteristics
Unmatched study population Matched study population
Parameter All patients
n = 288 (100%)
LS +
n = 84 (29.17%)
LS -
n = 204 (70.83%)
p-value LS +
n = 82 (33%)
LS -
n = 164 (67%)
p-value
Age [years]|; mean ± SD 69 ± 11 68 ± 11 70 ± 11 0.16 67 ± 11 68 ± 10 0.62
Sex [females] n (%) 70 (24) 19 (23) 51 (25) 0.76 19 (23) 41 (25) 0.88
Body mass index [kg/m2] mean ± SD 27 ± 7.0 27 ± 5.6 27 ± 7.5 0.71 27 ± 5.7 27 ± 8.2 0.81
Preoperative LVEF [%];mean ± SD 26 ± 7.3 26 ± 7.0 25 ± 8.0 0.14 26 ± 10 27 ± 11 0.47
Preoperative renal impairment; n (%)
• Stage 2 (GFR 85-120ml/min.)
• Stage 3 (GFR 51-85ml/min.)
• Stage 4 (GFR <51ml/min.)



























Preoperative atrial fibrillation; n (%) 96 (33) 29 (34) 67 (32) 0.48 29 (38) 57 (35) 0.67
Preoperative cardiopulmonary
resuscitation; n (%)
14 (4.9) 4 (4.8) 10 (4.9) 1.00 4 (4.9) 9 (5.5) 1.00
Preoperative invasive ventilation; n (%) 22 (7.6) 5 (6.0) 17 (8.3) 0.67 5 (6.1) 15 (9.2) 0.49
Preoperative use of inotropes and








































EuroSCORE II [%]; mean ± SD
• Isolated CABG group






























Type of Surgery; n (%)
• Isolated CABG
























Systolic blood pressure at induction of
anaesthesia [mmHg]; median (IQR)
113 (101–128) 109 (98–127) 115 (100–130) 0.87 115 (101–123) 119 (103–126) 0.74
Diastolic blood pressure at induction of
anaesthesia [mmHg]; median (IQR)
69 (60–82) 67 (59–81) 70 (59–83) 0.87 71 (61–87) 71 (65–79) 0.85
Extracorporeal circulation time [min.];
median (IQR)
98 (79–108) 93 (71–98) 103 (81–112) 0.24 114 ± 34 111 ± 26 0.58
Cardioplegic arrest time [min.];
median (IQR)
67 (51–89) 67 (50–90) 67 (53–86) 0.74 73 ± 30 72 ± 24 0.82
Demographics and intraoperative data of the study population before (left) and after propensity score matching (right). The unmatched population shows
significant differences between LS and control group with more severe chronic renal impairment and a more complex procedural profile in the LS group. After
matching, the groups are well balanced.
Abbreviations: CABG coronary artery bypass grafting surgery, GFR Glomerular filtration rate, LS Levosimendan, LVEF Left-ventricular ejection fraction
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of norepinephrine support was longer in the LS group
compared to the control group (median: 35h vs. 20h; p =
0.005). Otherwise, prevalence and duration of additional
medical circulatory support did not differ between the
groups.
Additional mechanical circulatory provided by intraop-
erative or postoperative initiation of intra-aortic balloon
pump (IABP) was more frequently applied in the LS-
group (21%) compared to the control group (6.1%; p =
0.0015). Postoperative ECLS (extracorporeal life support)
implantation was necessary more often in the LS-group
(6/82; 7.3%) compared to the control group without stat-
istical significance (6/164; 3.7%; p = 0.40).
Renal function
In the matched study population, preoperative renal
function shows no significant differences between LS
group and control group. However, a tendency towards
more severely impaired renal function in the LS group is
present (Table 1). In the postoperative course, glomeru-
lar filtration rates (GFR) showed an initial postoperative
decline in both groups with a recovery within four days








• Epinephrine required; n (%) 68 (83) 112 (68) <0.001
• Duration Epinephrine [h]; median (IQR) 19 (4.5–65) 10 (0–38) 0.01
• Nordrenaline required; n (%) 79 (96) 149 (91) 0.058
• Duration Nordrenaline [h]; median (IQR) 35 (15–68) 20 (11–47) 0.005
• Dobutamine required; n (%) 41 (50) 85 (52) 0.68
• Duration Dobutamine [h]; median (IQR) 25 (9–64) 12 (8–36) 0.83
• Milrinone required; n (%) 10 (12) 23 (14) 0.73
• Duration Milrinone [h]; median (IQR) 0.5 (0–14) 2.3 (0–18) 0.328
Mechanical circulatory support
IABP insertion; n (%)
• Intraoperatively 9 (11) 8 (4.9) 0.072
• Postoperatively 8 (9.8) 2 (1.2) 0.003
Duration IABP support [h]; median (IQR) 51 (40–73) 57 (26–75) 0.30
ECLS implantation; n (%) 6 (7.3) 6 (3.7) 0.40
Renal function
Postoperative GFR [ml/min.]; mean (95%-CI) 68 (50–86) 70 (60–81) 0.48
Postoperative GFR/preoperative GFR [ml/min.]; mean (95%-CI) 1.0 (0.9–1.1) 1.0 (0.9–1.1) 0.47
Acute kidney injury; n (%)
• AKIN I 14 (17) 37 (23) 0.22
• AKIN II 0 6 (3.7)
• AKIN III 6 (7.3) 6 (3.7)
New onset chronic dialysis; n (%) 1 (1.2) 3 (1.8) 1.00
Cardiac Injury
AF within 24h post-OP; n (%) 62 (76) 72 (44) <0.0001
CK until POD4 [U/l]; mean (95%-CI) 712 (368–1056) 619 (400–839) 0.402
CKMB until POD4 [U/l]; mean (95%-CI) 47 (23–72) 41 (29–54) 0.17
Length of stay
Postoperative LOS ICU [h]; median (IQR) 150 (71–200) 139 (67–168) 0.047
Postoperative LOS total [d]; median (IQR) 10 (8.0–13) 11 (7.0–14) 0.94
Comparison between patients who received prophylactic LS and patients who did not. Patients in the LS group show increased need for medical and mechanical
circulatory support (IABP) as well as an increased rate of postoperative atrial fibrillation, resulting in a prolonged demand for intensive care
Abbreviations: AF Atrial fibrillation, AKIN Acute kidney injury network, CK Creatinkinase, CKMB Creatinkinase, isoform MB, CRP C-reactive protein, ECLS Extracorporeal
life support, IABP Intra-aortic balloon pump, LOS Length of stay, LS Levosimendan, POD post-operative day, WBC White blood cell count
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postoperatively (data not shown). Mean postoperative
GFR and the ratio of postoperative GFR to preoperative
GFR did not differ between LS-group and control group
patients (Table 2). Multivariate regression analysis re-
vealed a reductive effect of LS on the incidence of acute
kidney injury (coefficient -1.37; p < 0.001). Interestingly,
also preoperative IABP implantation had a comparable
significant renoprotective effect (coefficient -1.69; p = 0.013)
while aortic cross clamping time had an incremental effect
on acute kidney injury (coefficient 1.45; p = 0.024) (Table 4).
Postoperative arrhythmias
We observed an overall increased incidence of atrial fibril-
lation within 24h postoperatively in patients receiving
prophylactic LS (62/82; 76%) compared to control group
patients (72/164; 44%; p < 0.0001; OR 4.0; 95%-CI 2.2–7-2)
(Table 2). This effect persisted in the differentiated com-
parison for CABG patients (OR 6.5; 95%-CI 1.8–21) and
combination procedure patients (OR 2.5; 95%-CI 1.0–3.8).
Linear regression confirmed prophylactic LS to be a pre-
dictor of postoperative AF (coefficient 0.86; p = 0.038). Also
preoperative IABP insertion and aortic cross clamping time
increased the risk of postoperative AF (Table 3).
In-hospital outcome
Patients in the LS group needed longer postoperative
intensive care (median 150h; IQR 71-200h) compared
to control group patients (median 139h; IQR 67-168h;
p = 0.047) (Table 2). Postoperative length of hospital
admission was 11 days (IQR 7–13 days), with no differ-
ence between LS group and control group.
30-days survival
Overall 30-days survival was reduced due to the patients’
high preoperative risk profile and a trend towards a
higher survival rate in patients receiving prophylactic LS
(69/82; 84%) compared to the control group (123/155;
79%; p = 0.40) was observed. Multivariate regression con-
firmed a tendency towards positive influence of LS on
30-days survival (coefficient 0.99; p = 0.12) while post-
operative IABP implantation (coefficient -2.36; p = 0.022)
and EuroSCORE II (coefficient -1.12; =0.0012) were sig-
nificant predictors of reduced 30-days survival. All other
investigated possible predictors did not influence 30-days
survival (Table 3).
Different subgroup analyses for 30-days survival were
conducted depending on (1) Procedural categories, (2)
Stages of renal impairment, (3) Preoperative LVEF, (4)
Categories of preoperative risk estimation using Euro-
SCORE II and (5) Concomitance of recent myocardial
infarction. Here, tendencies towards pronounced benefi-
cial effects of LS were observed for patients undergoing
isolated valve/aortic surgery (30-days survival LS group:
92% vs. control group: 70%; p = 0.24), for patients with
moderate chronic kidney injury/GFR 51–85ml/min.
(30-days survival LS group: 85% vs. control group: 66%;
p = 0.19), for patients with LVEF <25% (30-days survival
LS group: 81% vs. control group: 71%; p = 0.34), patients
who had no recent myocardial infarction (30-days survival
Table 3 Linear modeling for preoperative predictors influencing survival 30 days postoperatively, postoperative atrial fibrillation and
postoperative acute kidney injury
Responses 30-days survival Postoperative AF within 24h Postoperative acute kidney injury
Parameter Coefficient Standard error p-Value Coefficient Standard error p-Value Coefficient Standard error p-Value
Prophylactic LS 0.99 0.64 0.12 0.86 0.42 0.038 -1.37 0.53 0.0094
Preoperative IABP 0.40 0.69 0.56 2.19 0.70 0.0017 -1.69 0.68 0.013
Intraoperative IABP -0.58 0.89 0.51 0.91 0.76 0.23 0.29 0.77 0.71
Postoperative IABP -2.36 1.03 0.022 0.12 1.04 0.91 1.83 1.03 0.08
Aortic cross clamp time (log) -1.04 0.84 0.21 1.40 0.57 0.014 1.45 0.64 0.024
EuroSCORE II (log) -1.12 0.35 0.0012 -0.06 0.21 0.77 0.05 0.21 0.82
BMI (log) -2.87 1.71 0.093 1.02 1.46 0.48 1.69 1.52 0.26
Preoperative admission to ICU -0.34 0.66 0.60 0.42 0.59 0.48 0.95 0.59 0.11
Preoperative TNI -0.09 0.68 0.90 -1.87 0.70 0.0074 -0.39 0.60 0.52
Preoperative CRP (log) 0.04 0.16 0.79 0.03 0.12 0.80 0.16 0.13 0.20
Preoperative white blood cell
count (log)
-0.20 0.82 0.81 0.43 0.61 0.48 0.62 0.70 0.38
Multivariate regression analysis using generalized linear models was performed for the responses’30-days survival’, ‘postoperative new onset AF’ and ‘postoperative
acute kidney injury’. LS has no significant effect on 30-days survival but contributes significantly to postoperative AF and significantly reduces postoperative acute
kidney injury
Abbreviations: AF: Atrial fibrillation, BMI Body-mass index, CRP C-reactive protein, IABP Intra-aortic balloon pump, ICU Intensive care unit, LS Levosimendan,
TNI Troponin-I
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LS group: 91% vs. control group: 83%; p = 0.22) and pa-
tients with EuroSCORE II > 23 (30-days survival LS group:
70% vs. control group: 51%; p = 0.19) (Table 4).
Long-term survival
Median follow-up time was 610 days (IQR 130–1192
days). Follow up was complete for 238/246 (97%) patients.
Kaplan-Meier estimation was (1) applied for all patients
and (2) differentiated into the categories of surgical proce-
dures (Fig. 2). Survival curves showed an initial decline in
survival for both groups, representing the immediate post-
operative period. Subsequently, a slower decline was ob-
served in both groups. Overall survival was 76% (LS) and
79% (control) at one year, 73% (LS) and 76% (control) at
two years and 68% (LS) and 71% (control) at three years
postoperatively. In isolated CABG, LS patients tended to
reduced long-term survival compared with the control
group (Fig. 2b), contrarily to valve-group patients whose
long-term survival exceeded the control group’s survival
(Fig. 2c).
Discussion
We present real-world data from a high-risk patient col-
lective undergoing cardiac surgery with CPB. LS applica-
tion had no significant effect on overall 30-days survival
which is on one hand contradictory to previous studies
showing positive effects of prophylactic LS on short-term
survival [11, 12]. On the other hand, recent meta-analysis
of the available data revealed conflicting results on whether
or not LS reduces mortality [18, 19]. A differentiated ana-
lysis of our patient subgroups showed tendencies towards
positive effects of LS on 30-days survival in patients under-
going valve/aortic or combination procedures, patients
with moderate chronic renal impairment, patients who had
no recent myocardial infarction, patients with LVEF <25%
and patients with EuroSCORE II risk estimation scores
Table 4 30-days survival






All patients n = 237 69/82 (84) 123/155 (79) 0.40
Subgroup: procedural categories
Isolated CABG 26/32 (81) 58/68 (85) 0.77
Isolated valve surgery / ascending aortic surgery 11/12 (92) 23/33 (70) 0.24
Combination procedures 32/38 (84) 42/54 (78) 0.64
Subgroup analysis: renal impairment
GFR >120ml/min. 32/35 (91) 50/59 (85) 0.53
GFR 85–120ml/min. 12/13 (92) 47/55 (86) 1.00
GFR 51–85 ml/min. 17/20 (85) 19/29 (66) 0.19
GFR < 51ml/min. 5/9 (56) 4/7 (57) 1.00
Dialysis 3/5 (60) 3/5 (60) 1.00
Subgroup analysis: preoperative LVEF
LVEF <25% 29/36 (81) 46/65 (71) 0.34
LVEF 25–30% 21/23 (91) 41/48 (85) 0.60
LVEF 31–35% 19/23 (83) 36/42 (86) 0.72
Subgroup analysis: EuroSCORE II
EuroSCORE II <15 37/39 (95) 84/91 (92) 0.72
EuroSCORE II 15–17 3/4 (75) 4/5 (80) 1.00
EuroSCORE II 18–20 2/2 (100) 4/5 (80) 1.00
EuroSCORE II 21–23 4/5 (80) 3/3 (100) 1.00
EuroSCORE II >23 16/23 (70) 20/39 (51) 0.19
Subgroup analysis: Recent myocardial infarction
No recent myocardial infarction 50/55 (91) 72/87 (83) 0.22
Recent myocardial infarction 19/27 (70) 51/68 (75) 0.80
30-days survival data were available for 237/246 patients (96%). Overall, 30-days survival did not differ between patients who received prophylactic LS and patients who
did not. In the subgroup analyses depending on procedural categories, renal impairment, preoperative LVEF, EuroSCORE II and recent myocardial infarction, no significant
differences between LS group and control group were observed
Abbreviations: CABG Coronary artery bypass grafting surgery, GFR Glomerular filtration rate, LS Levosimendan, LVEF Left-ventricular ejection fraction
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>23. These findings suggest differential effects of LS de-
pending on procedure-related factors as well as on patient-
related factors. However, the size and design of our study
disables any final conclusion upon the significance of these
aspects.
LS reduced the incidence of postoperative acute renal
failure significantly. This result is consistent with previ-
ous studies showing renoprotective properties of LS in
cardiac surgical patients [8, 14].
Surprisingly, LS patients showed an excessively high
rate of atrial fibrillation within 24h postoperatively com-
pared to the control group (85% vs. 46%). As LS does not
increase intracellular calcium levels, it has been postulated
that LS might be advantageous compared to traditional
inotropes concerning the pro-arrhythmic effects. However,
our result is consistent with the SURVIVE I and II trials,
which also showed higher rates of arrhythmias in
ADHF-patients treated with LS [5].
Postoperative need for medical circulatory support was
increased in the LS group, resulting in a prolonged need
for intensive care. According to the lack of positive short-
term-effects of LS, long-term survival up to three years
postoperatively was not improved. Our observations are
consistent with a previous study by Lahtinen et al. that
compared prophylactic LS with placebo and reported simi-
lar survival in both groups 6 months postoperatively [20].
In summary, this study showed no or at least substan-
tially weaker effects of prophylactic LS compared to pre-
vious reports. It is well arguable, how retrospective data
should be weighed compared to methodically superior
prospective data: Prospective randomized-controlled stud-
ies are the gold standard for evaluation of clinical effects
of single interventions. However, this controlled setting
differs substantially from the clinical routine setting. This
might, among others, result in compliance bias and
contamination bias with consecutively reduced external
Fig. 2 Kaplan-Meier estimation for long-term survival. Vertical lines at one, two and three years postoperatively. a. Overall survival. After an initial
decline, survival remains stable after one two and three years in both groups. Survival curves do not differ. b. After isolated CABG, patients who
received LS showed lower survival without statistical significance. c. After isolated valve or aortic surgery, LS patients show stable survival compared to
reduced survival in the control group without statistical significance. D. After combination procedures, survival curves between the groups do
not differ. Abbreviations: CABG: Coronary artery bypass grafting surgery, LS: Levosimendan
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validity [21–24]. Thus, retrospective data, reflecting
real-life practice, could give important additional infor-
mation in order to classify the value of an intervention
in the daily routine and to generate hypotheses for fur-
ther studies.
Some aspects could be explanatory for a reduced over-
all LS-effect in the routine setting: First, the effect of LS
might have been underutilized by our therapeutic regime.
We did not apply an initial loading dose prior to continu-
ous infusion over 24h: A current expert opinion paper
states that an initial bolus at induction of anesthesia is a
feasible option without emphasizing explicit positive ef-
fects of loading dose administration [25]. Contrarily, appli-
cation of a LS bolus carries the risk of acute vasodilation
and hemodynamic destabilization and has been shown to
increase mortality in different clinical settings [14]. There-
fore, LS bolus administration has not been practiced in
our clinical routine. As we did not adjust LS dosing for
renal impairment, overdosing and increased side effects
might have resulted in some patients with severe renal
impairment.
Second, the timing of LS administration appears to be
critical: In our practice, LS was started after induction of
anesthesia, when LVEF was determined using transoeso-
phageal echocardiography. Without initial bolus, a steady-
state is achieved after 4h [25]. As median operation time
in our study population was 157 min., the full effect of LS
might not have been reached at the critical time points,
namely weaning from cardiopulmonary bypass and imme-
diate postoperative phase.
Third, patient selection might have been too restrict-
ive. We only administered prophylactic LS to patients
with severely reduced LVEF. It might be argued that
these patients’ precondition impedes positively influencing
their postoperative outcome. However, we even observed
a trend towards more pronounced survival benefit 30 days
postoperatively in patients with preoperative LVEF < 25%.
This observation is consistent with a meta-analysis of ran-
domized controlled trials on prophylactic LS in cardiac
surgery patients by Harrison et al. suggesting that patients
with preoperatively severely reduced LVEF benefit in a
greater extent from prophylactic LS compared to patients
with preoperatively normal LVEF [26].
On the other hand, methodical limitations of this
study could have biased the results:
First, this is a retrospective analysis with all its limitations.
In most of the patients, no continuous cardiac-output mon-
itoring was applied. Consecutively, medical circulatory sup-
port management was mainly based on individual decisions
by the treating physicians. This might have contributed to
suboptimal management of inotropes and vasopressors.
The study included a total of 288 patients, a relatively small
number of patients, with only 84 patients receiving prophy-
lactic LS. This study population might have been too small
to show possibly significant effects of prophylactic LS
properly.
A major limitation of this study is, that the criteria for
administration of LS were loose and decision individually
taken by the treating surgeon and anesthesiologist during
induction of anesthesia, which might have led to sampling
bias with sicker patients in the LS group. However, after
propensity score matching, risk estimation using Euro-
SCORE II and other baseline characteristics showed no
relevant difference between the groups. Nevertheless,
unknown confounders could still have biased the results.
Conclusions
Prophylactic LS application in high-risk patients with
preoperative LVEF ≤35% undergoing cardiac surgery had
no relevant positive effect on short- and long- term survival.
Although LS application was associated with improved post-
operative renal function, the occurrence of postoperative
atrial fibrillation was even increased compared to patients
who did not receive any preoperative preconditioning. Opti-
mal utilization of potential LS effects and translation of
these effects into long-term benefit has not been achieved
yet as critical questions are still unanswered: It remains un-
clear when and how to start prophylactic LS administration
and which patients undergoing which procedures benefit
most from this intervention. Furthermore, comparisons to
established preconditioning concepts (e.g., prophylactic
intra-aortic balloon counterpulsation) have to be sub-
stantiated in future studies. Based on the results of this
study, a prospective trial with 462 patients per group
would be needed to generate definitive results. Until
then, reluctance to include prophylactic LS application,
a cost-intensive (3.725€ per standard dose (12.5mg) [27])
non-subsidized intervention, into clinical routine seems
justified.
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